Elucidation of bone destroying diseases and establishment of therapy by regulation of inflammatory cytokines

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K10365
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 57060:Surgical dentistry-related
• Research Institution: Keio University
• Principal Investigator: Ryotaro Iwasaki 慶應義塾大学, 医学部(信濃町), 講師(非常勤) (30365390)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 破骨細胞 / 炎症性サイトカイン

Outline of Final Research Achievements

Animal models for anti resorptive agents related osteonecrosis of the jaw have been reported; however, most of them have focused on the administered anti-resorptive agents. We considered that oral bacteria may cause osteonecrosis based on its specific occurrence in the jaw. Thus, we established a our mouse model for anti-resorptive agents-related osteonecrosis of the jaw similar to its human counterpart, and conducted analyses using the model. Results suggested that inflammatory cytokines produced in macrophages due to bacterial infection can cause bone destroying disease typified by osteonecrosis. These results led us to consider that the elucidation of the mechanism of cytokine-regulated anti-inflammatory actions in the field of oral surgery would allow us to lead to potential new treatments for inflammatory diseases in the field of oral and maxillofacial surgery.

Free Research Field

骨代謝

Academic Significance and Societal Importance of the Research Achievements

口腔内の炎症を伴う骨破壊性疾患である骨吸収薬剤関連顎骨壊死のヒトに近似した動物モデルの確立は、発症機序の解明や治療法の開発には欠かすことのできないものである．要因は、未だはっきりとは解明されておらず、歯科医師は治療前の休薬の必要性の判断を含めた方針の決定に難渋している現状である。また、ビスフォスフォネート製剤が、骨粗鬆症の治療以外に、がん治療など様々な病態に使用されていることから、顎骨壊死の患者数は多い。現在、主たる治療法として行われている、外科的治療アプローチに代わる新しい治療戦略が求められており、新たな治療戦略の可能性を見出す可能性のある本研究の結果は極めて重要なものであると考えている．